News Content
Virgin proves its worth on pharma shipments without IATA's CEIV
VIRGIN Atlantic has been making headways into the pharma air cargo business by adopting their own path, opting to forego CEIV (Centre of Excellence for Independent Validators) certification.
In less than two years, the carrier has already doubled its share of the pharma market between the UK and North America, suggesting that its in-house Cool Chain product has the reputation to stand on its own, reports New York's Air Cargo World.
Virgin products manager Darren Sherlock said that the carrier is opting for a Wholesale Distribution Authority (WDA) licence.
"This demonstrates compliance with GDP guideline," he explained. "So we are not currently considering IATA CEIV."
According to data compiled by Statista, the global pharmaceutical market is expected to grow from US$1.07 trillion in 2015 to $1.4 trillion in 2020.
Virgin's vice president John Lloyd expects US to UK pharma to play a role, with that specific market forecast to grow by seven per cent a year through 2020.
He emphasised that "pharmaceutical traffic is a fast-growing part of Virgin's business," pointing out that the world's largest global pharma market is transatlantic.
With Virgin controlling 27 per cent of cargo capacity to and from the US, Mr Lloyd said, the airline is in a strong position to "give our customers the capacity, frequencies and service they need."
In less than two years, the carrier has already doubled its share of the pharma market between the UK and North America, suggesting that its in-house Cool Chain product has the reputation to stand on its own, reports New York's Air Cargo World.
Virgin products manager Darren Sherlock said that the carrier is opting for a Wholesale Distribution Authority (WDA) licence.
"This demonstrates compliance with GDP guideline," he explained. "So we are not currently considering IATA CEIV."
According to data compiled by Statista, the global pharmaceutical market is expected to grow from US$1.07 trillion in 2015 to $1.4 trillion in 2020.
Virgin's vice president John Lloyd expects US to UK pharma to play a role, with that specific market forecast to grow by seven per cent a year through 2020.
He emphasised that "pharmaceutical traffic is a fast-growing part of Virgin's business," pointing out that the world's largest global pharma market is transatlantic.
With Virgin controlling 27 per cent of cargo capacity to and from the US, Mr Lloyd said, the airline is in a strong position to "give our customers the capacity, frequencies and service they need."
Latest News
- For the first time, tianjin Port realized the whole process of dock operati...
- From January to August, piracy incidents in Asia increased by 38%!The situa...
- Quasi-conference TSA closes as role redundant in mega merger world
- Singapore says TPP, born again as CPTPP, is now headed for adoption
- Antwerp posts 5th record year with boxes up 4.3pc to 10 million TEU
- Savannah lifts record 4 million TEU in '17 as it deepens port
